Sawai Pharmaceutical Announces More Structured Proposal For Kyorin Merger, Eyeing Consolidation For Biosimilars In Japan
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Generics firm Sawai Pharmaceutical announced late Dec. 2 that it has proposed a merger with Kyorin Pharmaceutical to capitalize on alliance strength - a recent common trend in Japan - and create a biosimilar presence in the country, which has launched a nationwide campaign to increase generic usage. But Kyorin has spurned Sawai's advances before, and it is unclear whether the newest proposal will be sweet enough to progress
You may also be interested in...
Kyorin Rejects Sawai's Merger Proprosal, Leaving Japan's Generics Leader Scrambling Ahead Of Big Pharma Competition
TOKYO - In what amounted to a long-weekend consideration, Kyorin Pharmaceutical has rejected Sawai Pharmaceutical's proposal to initiate merger talks, adding a sense of urgency for the generics manufacturer as it tries to find business solutions to fend off generics competition in Japan from major pharma companies
Kyorin Rejects Sawai's Merger Proprosal, Leaving Japan's Generics Leader Scrambling Ahead Of Big Pharma Competition
TOKYO - In what amounted to a long-weekend consideration, Kyorin Pharmaceutical has rejected Sawai Pharmaceutical's proposal to initiate merger talks, adding a sense of urgency for the generics manufacturer as it tries to find business solutions to fend off generics competition in Japan from major pharma companies
Korea's Celltrion And Aprogen In Race To Sell Biosimilars In Japan
SEOUL - South Korean biotech firms Celltrion and Aprogen are racing to bring biosimilars of Roche's oncology agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis agent Remicade (infliximab) to Japan